Rezafungin acetate is a Small Molecule owned by Cidara Therapeutics, and is involved in 13 clinical trials, of which 11 were completed, 1 is ongoing, and 1 is planned.

Rezafungin acetate is an echinocandin antifungal agent. Echinocandins are inhibitors of beta-(1,3)-glucan synthesis, an action that damages fungal cell walls. 1,3-beta-D-glucan is more predominant in the cell walls of Candida and Aspergillus species. The drug candidate inhibits the 1,3-beta-glucan synthase. It leads to the osmotic lysis of the cell and eventual cell death.

The revenue for Rezafungin acetate is expected to reach a total of $2.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rezafungin acetate NPV Report.

Rezafungin acetate was originated by Seachaid Pharmaceuticals and is currently owned by Cidara Therapeutics.

Rezafungin acetate Overview

Rezafungin acetate is under development for the treatment and prophylaxis of aspergillosis in COVID-19 patients, pneumocystis pneumonia,Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum gypseum, systemic candida infections including candidemia and related cases of invasive candidiasis. The drug candidate is a long acting echinocandin. It is administered intravaginally, subcutaneously and intravenously as a solution and a gel. The drug candidate was under development for the treatment of vulvovaginal candidiasis.

Cidara Therapeutics Overview

Cidara Therapeutics (Cidara) formerly K2 Therapeutics is a biotechnology company. The company discovers, develops and commercializes novel anti-infectives including immunotherapies. Its pipeline products include rezafungin for the treatment of invasive fungal disease and CD388 for treating influenza. Cidara is investigating RSV AVC program for the treatment of respiratory syncytial virus (RSV), HIV AVC for human immunodeficiency viruses (HIV), CoV AVC for pan coronavirus. The company’s proprietary Cloudbreak, an antiviral platform for the fight against life-threatening infectious diseases that provides potent antiviral activity and immune system engagement in a single molecule. Cidara is headquartered in San Diego, California, the US.

The company reported revenues of (US Dollars) US$49.6 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$12.1 million in FY2020. The operating loss of the company was US$42.3 million in FY2021, compared to an operating loss of US$71.9 million in FY2020. The net loss of the company was US$42.5 million in FY2021, compared to a net loss of US$72.1 million in FY2020. The company reported revenues of US$6.2 million for the second quarter ended June 2022, a decrease of 12.6% over the previous quarter.

Quick View – Rezafungin acetate

Report Segments
  • Innovator
Drug Name
  • Rezafungin acetate
Administration Pathway
  • Intravenous
  • Subcutaneous
  • Vaginal
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.